Evidence map›Paper›PMID 41332840›Full record

ArticlemedRxiv : the preprint server for health sciences2025

Serum Procalcitonin: A Novel Tumor Biomarker for Diagnosis and Follow-Up in Fibrolamellar Hepatocellular Carcinoma.

Jean-Charles Nault, Claudia Campani, Theo Z Hirsch, Ethan Neumann, Waqar Arif, Sandrine Imbeaud, Marina Baretti, Marianne Ziol, Sabrina Sidali, Pauline Roger and 18 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

28 authors.

Jean-Charles NaultCentre de Recherche des Cordeliers, Université Paris Cité, Sorbonne Université, Inserm, F-75006, Paris, France.
Claudia CampaniCentre de Recherche des Cordeliers, Université Paris Cité, Sorbonne Université, Inserm, F-75006, Paris, France.
Theo Z HirschCentre de Recherche des Cordeliers, Université Paris Cité, Sorbonne Université, Inserm, F-75006, Paris, France.
Ethan NeumannJohns Hopkins Convergence Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Waqar ArifJohns Hopkins Convergence Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Sandrine ImbeaudCentre de Recherche des Cordeliers, Université Paris Cité, Sorbonne Université, Inserm, F-75006, Paris, France.
Marina BarettiJohns Hopkins Convergence Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Marianne ZiolCentre de Recherche des Cordeliers, Université Paris Cité, Sorbonne Université, Inserm, F-75006, Paris, France.
Sabrina SidaliCentre de Recherche des Cordeliers, Université Paris Cité, Sorbonne Université, Inserm, F-75006, Paris, France.
Pauline RogerCentre de Recherche des Cordeliers, Université Paris Cité, Sorbonne Université, Inserm, F-75006, Paris, France.
Manon AllaireAP-HP Sorbonne Université, Hôpital Universitaire Pitié-Salpêtrière, Service d'Hépatogastroentérologie, Paris, France.
Mohamed BouattourDepartment of Liver Cancer and Innovative Therapy Unit, Hôpital Beaujon, Assistance Publique-Hôpitaux de Paris, AP-HP. Nord, Clichy, France; Université Paris Cité, Centre de Recherche Sur L'Inflammation (CRI), INSERM, U1149, CNRS, Paris, France.
Fabio MarraDepartment of Experimental and Clinical Medicine, Internal Medicine and Hepatology Unit, University of Firenze, Florence, Italy.
Brice FresneauDepartment of Children and Adolescents Oncology, Gustave Roussy, Villejuif, France.
Neus LlarchBarcelona Clinic Liver Cancer (BCLC) Group, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Spain; Centro de Investigación Biomédica en Red en Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain; Liver Oncology Unit, Liver Unit, ICMDM Hospital Clinic de Barcelona, Barcelona, Spain; Universitat de Barcelona, Barcelona, Spain.
Jean-Marie PeronDepartment of Hepatogastroenterology, Rangueil University Hospital, 31059 Toulouse, France.
René GerolamiIHU Méditerranée Infection, Marseille, France, MEPHI, Aix-Marseille Université, Marseille, France.
Eric Nguyen KhacHepato-Gastroenterology Department, CHU Amiens, Amiens.
Pierre NahonCentre de Recherche des Cordeliers, Université Paris Cité, Sorbonne Université, Inserm, F-75006, Paris, France.
Nathalie Ganne-CarriéCentre de Recherche des Cordeliers, Université Paris Cité, Sorbonne Université, Inserm, F-75006, Paris, France.
Julien CaldéraroDepartment of Pathology, Henri-Mondor Hospital, MINT-Hep, Mondor Integrative Hepatology Assistance Publique-Hôpitaux Paris (AP-HP), Créteil, France. MINT-Hep, Mondor Integrative Hepatology, Créteil, France.
Aurélie BeaufrèreUniversité Paris Cité, Centre de Recherche Sur L'Inflammation (CRI), INSERM, U1149, Paris, France.
Valérie ParadisUniversité Paris Cité, Centre de Recherche Sur L'Inflammation (CRI), INSERM, U1149, Paris, France.
Catherine GuettierService d'anatomie pathologique, hôpitaux Bicêtre-Paul Brousse-Béclère, 78, rue du Général-Leclerc, 94270 Le Kremlin-Bicêtre, France; Faculté de médecine, université Paris-Saclay, Le Kremlin-Bicêtre, France.
CAPRIH FFCD cohort
Angela SuttonAP-HP, HUPSSD, Avicenne Hospital, Sorbonne Paris Nord University, Biochemistry Department, 93000 Bobigny, France.
Mark YarchoanJohns Hopkins Convergence Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Jessica Zucman-RossiCentre de Recherche des Cordeliers, Université Paris Cité, Sorbonne Université, Inserm, F-75006, Paris, France.

Funding

Translational Research Central ServicesP30CA006973 · NCI · JOHNS HOPKINS UNIVERSITY · PI ALAN KEITH MEEKER · 1985 to 2026
$208.6M
Neoantigen-specific T cell responses for Fibrolamellar Hepatocellular CarcinomaR01CA265009 · NCI · JOHNS HOPKINS UNIVERSITY · PI Paul G. Thomas, Mark Yarchoan · 2022 to 2026
$3.6M
Exploiting A Critical Vulnerability To Glutamine Antimetabolite Therapy in Fibrolamellar Hepatocellular Carcinoma (FLC)R01CA289041 · NCI · JOHNS HOPKINS UNIVERSITY · PI Mark Yarchoan · 2024 to 2026
$1.9M
NCI NIH HHS P30 CA006973NCI NIH HHS R01 CA265009NCI NIH HHS R01 CA289041
6 · The paper itself

Abstract

Introduction: Fibrolamellar carcinoma (FLC) is a rare primary liver cancer that predominantly affects young patients with normal known serum tumor biomarkers (alpha-fetoprotein (AFP) and CA19-9). An observation of a markedly elevated procalcitonin (PCT) in one patient prompted us to investigate the potential role of PCT as a biomarker in a larger cohort of FLC. Methods: We measured serum PCT levels in 34 samples from 18 patients with metastatic FLC and in 64 patients with hepatocellular carcinoma (HCC), 24 with cholangiocarcinoma (CCA), and 20 with cirrhosis. Using RNA sequencing, we analyzed Results: In 8 FLC from the European cohort, median serum PCT was significantly elevated (55.2 μg/l) compared to patients with HCC (0.14 μg/l), CCA (0.16 μg/l), and cirrhosis (0.11 μg/l; P=0.0005). These findings were independently validated in a U.S. cohort of 10 FLC patients compared to HCC and CCA (P=0.0002). Across these cohorts, elevated serum PCT was observed in 83% of FLC cases versus 3% of HCC and CCA cases (P<0.0001). In four patients with longitudinal measurements, changes in PCT levels correlated with radiologic response according to RECIST 1.1. RNA sequencing demonstrated significant overexpression of Conclusion: Procalcitonin is a sensitive and specific biomarker for FLC at both the serum and tumor levels among primary liver cancers, with potential utility in diagnosis and monitoring of treatment response.

Identifiers

PMID41332840
PMCPMC12668107

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.